12 Participants Needed

Venglustat + Cerezyme for Gaucher Disease

(LEAP Trial)

Recruiting at 17 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Genzyme, a Sanofi Company
Must be taking: Cerezyme
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications. However, you cannot take certain medications that affect liver enzymes or are known to cause cataracts, and you must avoid grapefruit products. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug Imiglucerase for Gaucher Disease?

Imiglucerase is effective in treating Gaucher Disease by improving symptoms like enlarged organs, anemia (low red blood cell count), and bone issues. Studies show it helps reduce spleen size, decreases the need for blood transfusions, and improves heart and lung symptoms in patients with Type 1 Gaucher Disease.12345

Is Venglustat + Cerezyme safe for humans?

The safety of Venglustat specifically is not detailed in the provided studies, but related treatments like imiglucerase and velaglucerase alfa for Gaucher disease have been generally well tolerated. Common mild to moderate side effects include headache, joint pain, and cold-like symptoms, with rare serious allergic reactions.36789

How is the drug Venglustat + Cerezyme unique for treating Gaucher Disease?

The combination of Venglustat and Cerezyme (imiglucerase) is unique because Venglustat is an investigational oral drug that can penetrate the brain and inhibit glucosylceramide synthase, potentially addressing neurological symptoms of Gaucher Disease type 3, which are not targeted by standard enzyme replacement therapies like imiglucerase alone.17101112

What is the purpose of this trial?

Part 1: Biomarker evaluation/screening phasePrimary Objectives:* Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease Type 3 (GD3) participants that distinguish GD3 from adult Gaucher disease Type 1 (GD1) participants* Screen adult GD3 participants who qualify for treatment with venglustat in Parts 2, Part 3, and Part 4 Parts 2 and 3: Combination treatment phasesPrimary objectives:* Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 participants* Evaluate the change in CSF central nervous system (CNS) biomarkers (glucosylceramide \[GL-1\] and lyso-glucosylceramide \[lyso-GL-1\]) from adult GD3 participants receiving venglustat in combination with Cerezyme (Part 2 only) Part 4: Extended treatment phase with monotherapyPrimary objectives:• Evaluate safety and tolerability of venglustat monotherapy in adult GD3 participants who have remained systemically stable on venglustat in combination with Cerezyme Parts 2 and 3: Combination treatment phasesSecondary Objectives:* Evaluate the pharmacokinetics (PK) of venglustat in adult GD3 participants* Evaluate the efficacy of venglustat in combination with Cerezyme in systemic disease in adult GD3 participants by assessing spleen volume, liver volume, hemoglobin level and platelet count* Evaluate the efficacy of venglustat in combination with Cerezyme on neurological function in adult GD3 participants by assessing Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)* Evaluate plasma biomarkers (lyso-GL-1 and GL-1) in adult GD3 participants Part 4: Extended treatment phase with monotherapySecondary objectives:* Evaluate the efficacy of venglustat in systemic disease in adult GD3 participants by assessing spleen volume, liver volume, hemoglobin level and platelet count* Evaluate the efficacy of venglustat on neurological function in adult GD3 participants by assessing Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)* Evaluate plasma biomarkers (lyso-GL-1 and GL-1) in adult GD3 participants

Research Team

CS

Clinical Sciences & Operations

Principal Investigator

Sanofi

Eligibility Criteria

Adults aged 18+ with Gaucher Disease Type 3 who have been on enzyme replacement therapy for at least 3 years and meet specific health goals can join. They must not be pregnant, agree to use contraception, and avoid grapefruit products. Exclusions include myoclonic seizures, severe kidney issues, hypersensitivity to Cerezyme, or other significant health problems.

Inclusion Criteria

I am willing to use birth control or practice abstinence during and after the study.
My Gaucher disease is under control, meeting all treatment goals.
My seizures are under control with medication that doesn't strongly affect CYP3A.
See 7 more

Exclusion Criteria

I experience sudden, brief muscle jerks.
I need regular blood transfusions to manage my condition.
I do not have any serious health issues other than Gaucher's disease that would stop me from joining.
See 16 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

45 days
1 visit (in-person)

Biomarker Evaluation

Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease Type 3 (GD3) participants

45 days

Combination Treatment

Participants receive venglustat in combination with Cerezyme to evaluate short-term and long-term safety and tolerability

Up to 10 years
Regular visits as per protocol

Extended Treatment with Monotherapy

Evaluate safety and tolerability of venglustat monotherapy in participants who have remained stable

Up to 10 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Imiglucerase
  • Venglustat
Trial Overview The trial tests the safety and effects of venglustat in combination with Cerezyme on brain biomarkers in adults with Gaucher Disease Type 3. It includes a screening phase followed by short-term and long-term treatment phases with both drugs, then an extension phase where only venglustat is given.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open label (OL) venglustatExperimental Treatment2 Interventions
Administered once a day orally for up to approximately 10 years. Participants will continue their usual dose of Cerezyme during Part 1, Part 2 and Part 3. There is no administration of Cerezyme in Part 4 unless administrated as rescue treatment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Genzyme, a Sanofi Company

Lead Sponsor

Trials
528
Recruited
186,000+
David Meeker profile image

David Meeker

Genzyme, a Sanofi Company

Chief Executive Officer since 2011

MD from the University of Vermont Medical School, Advanced Management Program at Harvard Business School

Jean-Paul Kress profile image

Jean-Paul Kress

Genzyme, a Sanofi Company

Chief Medical Officer since 2015

MD from Faculte Necker-Enfants Malades, Paris

Findings from Research

In a study involving 211 patients with type 1 Gaucher disease, velaglucerase alfa was found to have a safety profile similar to that of imiglucerase, with only 17.1% of previously treated patients experiencing related adverse events.
The treatment was well-tolerated, with infusion-related adverse events occurring in 13.3% of patients, primarily during the first three infusions, and no significant immune responses observed in treatment-naïve patients.
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.Pastores, GM., Rosenbloom, B., Weinreb, N., et al.[2022]
In a Phase 2 trial involving 11 adults with Gaucher disease type 3, the investigational drug venglustat, when added to standard enzyme replacement therapy, demonstrated acceptable safety and tolerability over one year, with no serious adverse events reported.
Venglustat treatment resulted in significant reductions in glucosylceramide and glucosylsphingosine levels in both plasma and cerebrospinal fluid, suggesting potential efficacy in addressing the biochemical aspects of the disease, although overall neurological function showed signs of deterioration over time.
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.Schiffmann, R., Cox, TM., Dedieu, JF., et al.[2023]

References

Imiglucerase and its use for the treatment of Gaucher's disease. [2019]
Imiglucerase treatment in Gaucher's disease. [2016]
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. [2016]
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. [2016]
Individualization of long-term enzyme replacement therapy for Gaucher disease. [2022]
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. [2022]
Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy. [2007]
[Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease]. [2016]
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. [2021]
Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. [2023]
Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease. [2019]
Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security